While several drugmakers may be circling coveted buyout target Medivation, so far, Sanofi is the only one that’s come through with a bid. But that could all be…

BioMarin shares climbed more than 10% Thursday on talk of a potential takeover. And if that scenario sounds familiar, that’s because it is.

When Medivation CEO David Hung talked up his company’s cancer candidate talazoparib Wednesday, the message was clear for the Big Pharmas and Big Biotechs…

Medivation’s hostile fight with bidder Sanofi is over, and a new sale process has just begun.

Plenty of Big Pharma players are reportedly eying Medivation. But who’s most likely to make a bid?

Tesaro’s good fortune may be Big Pharma’s bad luck. The biotech posted “overwhelmingly positive” data on its PARP inhibitor niraparib, boosting hopes for…

Once Medivation is off the table, where might drugmakers turn next for M&A? The analysts at Credit Suisse have a few ideas.

Some specialty pharma companies have recently put the brakes on dealmaking--but Horizon Pharma, on the other hand, may be gearing up for more.

Teva’s massive deal to buy Allergan’s generics business continues to ripple its way through the industry. Australia’s Mayne Pharma has scooped up 42 products…